A Phase 1 interventional study of MEDI8897 Intravenous and Placebo in Respiratory Syncytial Virus Infections, sponsored by MedImmune LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-11-28.
Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca — none open to participants now, none under way, none of them phase 3. Respiratory Syncytial Virus Infections · AstraZeneca.
Among the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca, this one is the 5th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2014, is one of 4 in phase 1, and was the 9th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →None of the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca is open now. The open studies under Respiratory Syncytial Virus Infections, anywhere →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 49 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 4
First in 2003; this study’s year is marked. 1 started in 2014.
This study's enrollment of 342 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 239 across the 12 interventional studies, 233 across the 2 observational. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under MedImmune LLC, one of the names counted as AstraZeneca. Under that name alone:
MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the safety, tolerability and pharmacokinetics of an extended half-life anti-respiratory syncytial virus (RSV) monoclonal antibody compared to placebo when administered to healthy adult participants.
This was a phase 1, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability and pharmacokinetics of MEDI8897 compared to placebo when administered to healthy adult participants. There were 136 participants randomized to receive MEDI8897 or placebo at one site. Investigational product was delivered intravenously (IV) to 3 cohorts and intramuscularly (IM) to 2 cohorts. 4 different dose levels of investigational product were evaluated across the 5 cohorts. Participants were followed for approximately 1 year.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single fixed dose of 300 mg MEDI8897 intravenous infusion on Day 1.
Drug: MEDI8897 Intravenous
Participants received a single fixed dose of 1000 mg MEDI8897 intravenous infusion on Day 1.
Drug: MEDI8897 Intravenous
Participants received a single fixed dose of 3000 mg MEDI8897 intravenous infusion on Day 1.
Drug: MEDI8897 Intravenous
Participants received a single fixed dose of 100 mg MEDI8897 intramuscular injection on Day 1.
Drug: MEDI8897 Intramuscular
Participants received a single fixed dose of 300 mg MEDI8897 intramuscular injection on Day 1.
Drug: MEDI8897 Intramuscular
Participants received placebo on Day 1.
Drug: Placebo
Participants received a single fixed dose of 300 mg MEDI8897 intravenous infusion on Day 1.
Participants received placebo on Day 1.
Participants received a single fixed dose of 1000 mg MEDI8897 intravenous infusion on Day 1.
Participants received a single fixed dose of 3000 mg MEDI8897 intravenous infusion on Day 1.
Participants received a single fixed dose of 100 mg MEDI8897 intramuscular injection on Day 1.
Participants received a single fixed dose of 300 mg MEDI8897 intramuscular injection on Day 1.
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
An adverse event (AE) is defined as events present at baseline that worsened in intensity after administration of investigational products or events absent at baseline that emerged after administration of study drug, for the period extending to 391 (Day 361 ± 30 days) days after the last dose of study drug.
Time frame: From start of study drug administration up to Day 391 (Day 361 +/- 30 days)
Time to Reach Maximum Observed Serum Concentration (Tmax) of MEDI8897
The Tmax is defined as actual sampling time to reach maximum observed MEDI8897 concentration. The reported Standard Deviation values are actually Relative Standard Deviation (RSD) values (that is, Coefficient of Variation).
Time frame: Predose, End of Dosing (IV Arms), 8 Hour Postdose, Day 2, 4, 6, 8, 15, 22, 31, 61, 91, 121, 151, 181, 271 and 361
Maximum Observed Serum Concentration (Cmax) for MEDI8897
The Cmax is the maximum observed serum concentration of MEDI8897. The reported Standard Deviation values are actually Relative Standard Deviation (RSD) values (that is, Coefficient of Variation).
Time frame: Predose, End of Dosing (IV Arms), 8 Hour Postdose, Day 2, 4, 6, 8, 15, 22, 31, 61, 91, 121, 151, 181, 271 and 361
Area Under the Serum Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) for MEDI8897
The AUC (0-infinity) is the area under the serum concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the serum concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant. The reported Standard Deviation values are actually Relative Standard Deviation (RSD) values (that is, Coefficient of Variation).
Time frame: Predose, End of Dosing (IV Arms), 8 Hour Postdose, Day 2, 4, 6, 8, 15, 22, 31, 61, 91, 121, 151, 181, 271 and 361
Terminal Phase Elimination Half Life (t1/2) for MEDI8897
The terminal elimination half-life (t1/2) is the time measured for the serum concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z). Here 'n' signifies participants evaluable for specified categories, for each arm, respectively. The reported Standard Deviation values are actually Relative Standard Deviation (RSD) values (that is, Coefficient of Variation).
Time frame: Predose, End of Dosing (IV Arms), 8 Hour Postdose, Day 2, 4, 6, 8, 15, 22, 31, 61, 91, 121, 151, 181, 271 and 361
Systemic Clearance (CL) for MEDI8897
Systemic Clearance (CL) is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after the dose was estimated by dividing the total administered dose by the Area Under the Concentration-Time Curve From Time Zero to Infinite Time (AUC\[0-infinity\]). Apparent clearance (CL/F) for the IM dose groups. The reported Standard Deviation values are actually Relative Standard Deviation (RSD) values (that is, Coefficient of Variation).
Time frame: Predose, End of Dosing (IV Arms), 8 Hour Postdose, Day 2, 4, 6, 8, 15, 22, 31, 61, 91, 121, 151, 181, 271 and 361
Volume of Distribution (Vz) for MEDI8897
The Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a study drug. Apparent volume of distribution (Vz/F) for the IM dose groups. The reported Standard Deviation values are actually Relative Standard Deviation (RSD) values (that is, Coefficient of Variation).
Time frame: Predose, End of Dosing (IV Arms), 8 Hour Postdose, Day 2, 4, 6, 8, 15, 22, 31, 61, 91, 121, 151, 181, 271 and 361
Number of Participants With Positive Anti-Drug Antibody (ADA)
Participants were tested for anti-drug antibody to MEDI8897 prior to enrollment, predose and postdose.
Time frame: Predose and Day 15, 31, 91, 181, 271 and 361
| Milestone | Placebo | MEDI8897 300 Milligram (mg) Intravenous (IV) | MEDI8897 1000 Milligram (mg) Intravenous (IV) | MEDI8897 3000 Milligram (mg) Intravenous (IV) | MEDI8897 100 Milligram (mg) Intramuscular (IM) | MEDI8897 300 Milligram (mg) Intramuscular (IM) |
|---|---|---|---|---|---|---|
| Started | 34 | 6 | 6 | 6 | 6 | 78 |
| Completed | 28 | 5 | 5 | 6 | 6 | 75 |
| Not completed | 6 | 1 | 1 | 0 | 0 | 3 |
| Withdrew: Lost to follow-up | 4 | 1 | 1 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawn by site due to noncompliance | 1 | 0 | 0 | 0 | 0 | 0 |
An adverse event (AE) is defined as events present at baseline that worsened in intensity after administration of investigational products or events absent at baseline that emerged after administration of study drug, for the period extending to 391 (Day 361 ± 30 days) days after the last dose of study drug.
| participants | Placebo | MEDI8897 300 Milligram (mg) Intravenous (IV) | MEDI8897 1000 Milligram (mg) Intravenous (IV) | MEDI8897 3000 Milligram (mg) Intravenous (IV) | MEDI8897 100 Milligram (mg) Intramuscular (IM) | MEDI8897 300 Milligram (mg) Intramuscular (IM) |
|---|---|---|---|---|---|---|
| TEAEs | 21 | 3 | 3 | 5 | 4 | 48 |
| TESAEs | 0 | 0 | 0 | 0 | 0 | 2 |
The Tmax is defined as actual sampling time to reach maximum observed MEDI8897 concentration. The reported Standard Deviation values are actually Relative Standard Deviation (RSD) values (that is, Coefficient of Variation).
| Day | MEDI8897 300 Milligram (mg) Intravenous (IV) | MEDI8897 1000 Milligram (mg) Intravenous (IV) | MEDI8897 3000 Milligram (mg) Intravenous (IV) | MEDI8897 100 Milligram (mg) Intramuscular (IM) | MEDI8897 300 Milligram (mg) Intramuscular (IM) |
|---|---|---|---|---|---|
| Time to Reach Maximum Observed Serum Concentration (Tmax) of MEDI8897 | 0.078 ± 172 | 0.059 ± 0 | 0.209 ± 62.7 | 5.46 ± 71.4 | 9.42 ± 78.4 |
The Cmax is the maximum observed serum concentration of MEDI8897. The reported Standard Deviation values are actually Relative Standard Deviation (RSD) values (that is, Coefficient of Variation).
| microgram per milliliter (mcg/ml) | MEDI8897 300 Milligram (mg) Intravenous (IV) | MEDI8897 1000 Milligram (mg) Intravenous (IV) | MEDI8897 3000 Milligram (mg) Intravenous (IV) | MEDI8897 100 Milligram (mg) Intramuscular (IM) | MEDI8897 300 Milligram (mg) Intramuscular (IM) |
|---|---|---|---|---|---|
| Maximum Observed Serum Concentration (Cmax) for MEDI8897 | 96.98 ± 21.9 | 333.80 ± 22.4 | 1163.32 ± 23.8 | 20.40 ± 29.4 | 47.48 ± 26.2 |
The AUC (0-infinity) is the area under the serum concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the serum concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant. The reported Standard Deviation values are actually Relative Standard Deviation (RSD) values (that is, Coefficient of Variation).
| Day*microgram per milliliter | MEDI8897 300 Milligram (mg) Intravenous (IV) | MEDI8897 1000 Milligram (mg) Intravenous (IV) | MEDI8897 3000 Milligram (mg) Intravenous (IV) | MEDI8897 100 Milligram (mg) Intramuscular (IM) | MEDI8897 300 Milligram (mg) Intramuscular (IM) |
|---|---|---|---|---|---|
| Area Under the Serum Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) for MEDI8897 | 6714.75 ± 21.7 | 25320.68 ± 17 | 63580.33 ± 10.4 | 2249.11 ± 17.9 | 5193.73 ± 32.1 |
The terminal elimination half-life (t1/2) is the time measured for the serum concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z). Here 'n' signifies participants evaluable for specified categories, for each arm, respectively. The reported Standard Deviation values are actually Relative Standard Deviation (RSD) values (that is, Coefficient of Variation).
| Day | MEDI8897 300 Milligram (mg) Intravenous (IV) | MEDI8897 1000 Milligram (mg) Intravenous (IV) | MEDI8897 3000 Milligram (mg) Intravenous (IV) | MEDI8897 100 Milligram (mg) Intramuscular (IM) | MEDI8897 300 Milligram (mg) Intramuscular (IM) |
|---|---|---|---|---|---|
| Terminal Phase Elimination Half Life (t1/2) for MEDI8897 | 116.52 ± 19.6 | 92.0 ± 12.6 | 89.81 ± 18.2 | 102.61 ± 11.3 | 85.29 ± 30.8 |
Systemic Clearance (CL) is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after the dose was estimated by dividing the total administered dose by the Area Under the Concentration-Time Curve From Time Zero to Infinite Time (AUC\[0-infinity\]). Apparent clearance (CL/F) for the IM dose groups. The reported Standard Deviation values are actually Relative Standard Deviation (RSD) values (that is, Coefficient of Variation).
| ml per day | MEDI8897 300 Milligram (mg) Intravenous (IV) | MEDI8897 1000 Milligram (mg) Intravenous (IV) | MEDI8897 3000 Milligram (mg) Intravenous (IV) | MEDI8897 100 Milligram (mg) Intramuscular (IM) | MEDI8897 300 Milligram (mg) Intramuscular (IM) |
|---|---|---|---|---|---|
| Systemic Clearance (CL) for MEDI8897 | 46.05 ± 17.3 | 40.33 ± 15.4 | 47.60 ± 10.6 | 45.46 ± 15.4 | 64.60 ± 37.7 |
The Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a study drug. Apparent volume of distribution (Vz/F) for the IM dose groups. The reported Standard Deviation values are actually Relative Standard Deviation (RSD) values (that is, Coefficient of Variation).
| milliliter (ml) | MEDI8897 300 Milligram (mg) Intravenous (IV) | MEDI8897 1000 Milligram (mg) Intravenous (IV) | MEDI8897 3000 Milligram (mg) Intravenous (IV) | MEDI8897 100 Milligram (mg) Intramuscular (IM) | MEDI8897 300 Milligram (mg) Intramuscular (IM) |
|---|---|---|---|---|---|
| Volume of Distribution (Vz) for MEDI8897 | 7694.15 ± 24.8 | 5426.89 ± 26.7 | 6137.69 ± 18.5 | 6808.78 ± 24.5 | 7455.90 ± 34.0 |
Participants were tested for anti-drug antibody to MEDI8897 prior to enrollment, predose and postdose.
| participants | Placebo | MEDI8897 300 Milligram (mg) Intravenous (IV) | MEDI8897 1000 Milligram (mg) Intravenous (IV) | MEDI8897 3000 Milligram (mg) Intravenous (IV) | MEDI8897 100 Milligram (mg) Intramuscular (IM) | MEDI8897 300 Milligram (mg) Intramuscular (IM) |
|---|---|---|---|---|---|---|
| Predose | 3 | 0 | 0 | 0 | 0 | 5 |
| At Any Time Postdose | 5 | 0 | 1 | 0 | 0 | 13 |
Collected over From Screening to Postdose Follow-up (up to 391 Days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/34 (0%) | 21/34 (61.8%) |
| MEDI8897 300 Milligram (mg) Intravenous (IV) | — | 0/6 (0%) | 3/6 (50%) |
| MEDI8897 1000 Milligram (mg) Intravenous (IV) | — | 0/6 (0%) | 3/6 (50%) |
| MEDI8897 3000 Milligram (mg) Intravenous (IV) | — | 0/6 (0%) | 5/6 (83.3%) |
| MEDI8897 100 Milligram (mg) Intramuscular (IM) | — | 0/6 (0%) | 4/6 (66.7%) |
| MEDI8897 300 Milligram (mg) Intramuscular (IM) | — | 2/78 (2.6%) | 48/78 (61.5%) |
| Event | Placebo | MEDI8897 300 Milligram (mg) Intravenous (IV) | MEDI8897 1000 Milligram (mg) Intravenous (IV) | MEDI8897 3000 Milligram (mg) Intravenous (IV) | MEDI8897 100 Milligram (mg) Intramuscular (IM) | MEDI8897 300 Milligram (mg) Intramuscular (IM) |
|---|---|---|---|---|---|---|
| AppendicitisInfections and infestations | 0/34 | 0/6 | 0/6 | 0/6 | 0/6 | 1/78 |
| Gun shot woundInjury, poisoning and procedural complications | 0/34 | 0/6 | 0/6 | 0/6 | 0/6 | 1/78 |
| Event | Placebo | MEDI8897 300 Milligram (mg) Intravenous (IV) | MEDI8897 1000 Milligram (mg) Intravenous (IV) | MEDI8897 3000 Milligram (mg) Intravenous (IV) | MEDI8897 100 Milligram (mg) Intramuscular (IM) | MEDI8897 300 Milligram (mg) Intramuscular (IM) |
|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 2/34 | 0/6 | 0/6 | 2/6 | 0/6 | 3/78 |
| Urinary tract infectionInfections and infestations | 1/34 | 0/6 | 0/6 | 0/6 | 2/6 | 4/78 |
| Upper respiratory tract infectionInfections and infestations | 3/34 | 1/6 | 1/6 | 0/6 | 1/6 | 16/78 |
| HeadacheNervous system disorders | 6/34 | 0/6 | 1/6 | 1/6 | 0/6 | 7/78 |
| Lacrimation increasedEye disorders | 1/34 | 0/6 | 1/6 | 0/6 | 0/6 | 0/78 |
| ConstipationGastrointestinal disorders | 1/34 | 1/6 | 0/6 | 0/6 | 0/6 | 1/78 |
| FlatulenceGastrointestinal disorders | 0/34 | 0/6 | 0/6 | 1/6 | 0/6 | 0/78 |
| Food poisoningGastrointestinal disorders | 0/34 | 0/6 | 0/6 | 1/6 | 0/6 | 0/78 |
| Injection site painGeneral disorders | 0/34 | 0/6 | 0/6 | 0/6 | 1/6 | 1/78 |
| ConjunctivitisInfections and infestations | 0/34 | 0/6 | 0/6 | 1/6 | 0/6 | 1/78 |
The As-treated Population included participants who receive any study investigational product.
| Age, Continuous(Years) | Placebo | MEDI8897 300 Milligram (mg) Intravenous (IV) | MEDI8897 1000 Milligram (mg) Intravenous (IV) | MEDI8897 3000 Milligram (mg) Intravenous (IV) | MEDI8897 100 Milligram (mg) Intramuscular (IM) | MEDI8897 300 Milligram (mg) Intramuscular (IM) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 29.2 ± 8.6 | 34.5 ± 8.6 | 34.3 ± 5.6 | 33.5 ± 6.7 | 30.7 ± 7.8 | 30.3 ± 7.9 | 30.5 ± 8.0 |
| Sex: Female, Male(Participants) | Placebo | MEDI8897 300 Milligram (mg) Intravenous (IV) | MEDI8897 1000 Milligram (mg) Intravenous (IV) | MEDI8897 3000 Milligram (mg) Intravenous (IV) | MEDI8897 100 Milligram (mg) Intramuscular (IM) | MEDI8897 300 Milligram (mg) Intramuscular (IM) | Total |
|---|---|---|---|---|---|---|---|
| Female | 19 | 4 | 2 | 3 | 6 | 39 | 73 |
| Male | 15 | 2 | 4 | 3 | 0 | 39 | 63 |
The record gives a start of Apr 2014, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2016, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nirsevimab
Respiratory Syncytial Virus Infections →